Launch

medicine

Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine

(MENAFN – Newsfile Corp) Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine

Vancouver, British Columbia–(Newsfile Corp. – November 30, 2020) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (” Lobe ” or the ” Company “) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (” NAC “) for the treatment of mild traumatic brain injury/concussion (” mTBI “) with post-traumatic stress disorder (” PTSD “). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

The Miller School of Medicine is an internationally recognized leader in medical research, ranked No. 39 among the top medical schools in the nation by Blue Ridge Institute for Medical Research. In 2019, the medical school submitted 1,968 research proposals and was awarded $149 million in research funding from the National Institutes of Health (NIH).

Advances in neuro-diagnostic assessment have revealed mild traumatic brain injury (concussion) is more common than previously thought and potentially associated with a host of negative health outcomes. The Centers for Disease Control (” CDC “) estimates that there are 3 million emergency room visits and over 230,000 hospitalizations due to TBI in any given year in the United States alone. Also, at the same time there are 5.3 million Americans living with the effects of mTBI (a 53% increase over ten years ago). The World Health Organization calls traumatic brain injury a “silent epidemic” that affects over 70 million individuals across the world. The United States Department of Defense estimates that over 345,000 individuals are affected by mTBI and that 20% of all service members who deploy suffer mTBI. mTBI and PTSD are significant health care issues that often co-occur and impact each other.

Dr. Hoffer, the principal investigator on the study, said, “This a very important extension of our work with NAC and other medicines to identify new treatments for mTBI and PTSD. We are hopeful that this new combination of psilocybin with NAC will lead us to better solutions for those suffering from mTBI and/or PTSD.”

Maghsoud Dariani, Chief Science Officer of Lobe said, “We are very excited to begin the preclinical studies in collaboration with Dr.

Read More
fitness

Anna Victoria’s Postpartum Journey Inspired Her to Launch New Programs On Her Fitness App

2020 has been a big year for Anna Victoria. On the personal front, after a two-year battle with infertility, the Fit Body Guides creator welcomed her first child, Aurora Vittoria Ferretti, in August.



a group of people posing for a photo: Anna Victoria


© Provided by Shape
Anna Victoria

But Victoria has been busy at work, too. She’s been developing a series of updates to her Fit Body app, including the launch of a pregnancy workout program and the introduction of three new trainers.

Victoria says being a first-time mom motivated her to bring something new to the Fit Body app that would specifically cater to her fellow mamas. “You hear about how hard being a mom is, but you really can’t comprehend it until you go through it yourself,” she tells Shape. “There are so many emotions and so many new things you have to learn — and in the midst of it all, you’re constantly feeling like you’re doing something wrong.”

In addition to emotional ups and downs, Victoria says she’s had some physical challenges during her postpartum journey as well. One week after her (unplanned) C-section in August, she says, she couldn’t even sit up on her own. “It took me two weeks to walk without pain,” she shares. “When you have a newborn, you don’t expect to be going through that. It’s a lot to juggle, which has, at times, been very hard.” (Related: 7 Moms Share What It’s Really Like to Have a C-Section)



a group of people posing for a photo: Along with a new pregnancy-focused workout program, the trainer will also be welcoming three new trainers to the Fit Body app.


© Anna Victoria
Along with a new pregnancy-focused workout program, the trainer will also be welcoming three new trainers to the Fit Body app.

It wasn’t until she was three weeks postpartum that Victoria started feeling more like herself again, she says. “Every week since then, I’ve gotten exponentially better,” she explains.

But when she was cleared by her doctor to work out again in September at around six weeks postpartum, Victoria knew she wasn’t physically capable of diving back in just yet. “I couldn’t even think about it,” she says. “I know my body and I just wasn’t ready.”

Instead, from weeks 6-8, Victoria says she focused on breathing techniques to start feeling in tune with her body again. “I felt like building a mind-muscle connection with my core was a good place to start,” she says. (Related: Fitness Influencer Anna Victoria Fights Back Against Pregnancy Workout Shaming)

The following week, Victoria started inching her way back into a workout routine. Her first “true” workout, she says, was a beginner-level, low-impact lower-body workout from her Fit Body app. “I even ditched the weights, but I still couldn’t walk for a week [after that first workout],” she admits. “I didn’t expect to be that sore! It was so hard.”

The experience was not only humbling for Victoria, a seasoned trainer, but it also inspired her to bring more pregnancy-, postpartum-, and beginner-friendly workouts to the Fit Body app — plus a new group of trainers to teach them.

What to Expect From the New Fit Body App Updates

If

Read More
medicine

MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines

NEW YORK, Nov. 24, 2020 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, is establishing a digital medicine division known as Albert. Albert is in the process of assembling and recruiting a leading team of technologists, therapists, and clinical drug development experts to help the company research, develop and build an integrated technical platform and comprehensive toolset aimed at delivering psychedelic inspired medicines and experiential therapies combined with digital therapeutics.

Digital therapeutics are defined as evidence-based therapeutic interventions for patients to prevent, manage, or treat a mental disorder or disease. Pairing digital tools, such as wearables and the latest in machine learning, with psychedelic assisted therapies, can give healthcare providers the ability to optimize and better understand the patient journey and therapeutic outcomes from pre-care through to after-care.

MindMed Co-Founder and Co-CEO J.R. Rahn said, “We believe that the next frontier in psychedelic medicine will be to quantify with great precision psychedelic assisted therapy’s impact on patient populations. This new division will not only build apps, technologies and other platforms to help the patient, but hopefully also make the medical community comfortable with this novel treatment paradigm for mental health and addiction by measuring the potential value to their patient populations and ultimate savings to insurers.”

Recent advancements in digital therapeutics have the potential to enable a real time assessment of efficacy in both clinical trials and real-world settings leading to a more robust understanding of the value of a treatment and long-term impact on patient outcomes.

MindMed’s clinical team under the leadership of President and Head of Clinical Dr. Miri Halperin Wernli is designing an experimental clinical trial that pairs non-hallucinogenic psychedelic inspired medicines such as microdoses of LSD with digital therapeutics to track, engage and influence patient behavior. MindMed intends to announce full details of this clinical trial once MindMed and its scientific collaborators finalize the protocol design for submission to relevant health regulators.

Dr. Miri Halperin Wernli said, “This is a perfect moment for digital medicine solutions to come to patients to help support behavioral change, measure and enhance psychiatric care and health outcomes. Our intention is to use digital therapeutics alongside pharmaceutical medicines to maximize one another’s value to the patient and for the healthcare system. The two classes of medicine, along with psychotherapy and various forms of cognitive behavioral therapies, must be regarded as complementary to enhance outcomes, which will create new opportunities to improve quality of care and patient outcomes and drive behavior change at scale.”

About MindMed

MindMed is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to the company’s groundbreaking approach to developing the next-generation of psychedelic inspired medicines and therapies.

MindMed trades on the Canadian

Read More
fitness

Silofit Expands Network of Private, On-Demand Fitness Spaces with the Launch of Three Micro-Gyms in Toronto

TORONTO & MONTRÉAL–(BUSINESS WIRE)–At a time when the out-of-home fitness industry is contracting amid the pandemic, Silofit is expanding its network of private fitness spaces. The company today announced it has launched three new micro-gyms in the downtown Toronto core to meet the growing demand for its fully equipped spaces. Silofit also announced that its seed funding round was extended and closed at CAD$3.5 million, up from the previously stated $1 million.

Silofit opened its first space (“Silo”) in Toronto last month, and two additional Silos opened today. Each space is operational daily from 6:00 a.m. to 11:00 p.m. and can accommodate 60 bookings / hours of training per week. The first space has been fully booked since it opened, and the two new spaces are already fully booked for the next two weeks. Given the demand for its private, on-demand fitness spaces, Silofit plans to open another 12 locations in Toronto in 2021 and will also expand to the U.S. market.

Silofit leases small, unused office spaces and turns them into private micro-gym studios that can be booked by fitness trainers for 1:1 client training or by individual gym-goers, on-demand, and by the hour, using the Silofit app. Each Silo features all the workout equipment anyone would expect of a traditional gym, including cardio equipment such as a bike and rower, and weight options including a squat rack, cable machine, dumbbells, kettlebells, medicine balls, TRX, and more. The Silofit app is used to locate a space, and select the date, time, and duration for a fitness session. Ahead of the booked session, users receive instructions for using the Silo along with a unique access code to unlock the door. COVID-19 safety protocols are in place, including the sanitization of each space between users.

“We launched our business in 2018 with a view to disrupting the out-of-home fitness industry. And today, while most gyms are contracting because of the pandemic, we are accelerating our expansion plans given the demand we are seeing for our space,” said Wilfred Valenta, co-founder and CEO of Silofit. “In the past year, we have grown from two Silos to eight. And now, with the additional funding and strategic support from our investors – which are in the technology, sports, and real estate sectors – we are incredibly well positioned to continue on this path.”

Silofit now operates a total of eight Silos, including five in Montreal. Three of its Montreal Silos were launched in the past six months and two were operational this time last year.

Seed funding round extended, closing at $3.5 million

In November 2019, Silofit announced that it had raised $1 million in a seed funding round led by Whitecap Venture Partners and Courtside Ventures, with participation from NFL player, Ndamukong Suh. Given the growth potential for Silofit amid the pandemic, the round was extended earlier this year, bringing the total amount of seed funding raised to $3.5 million. The seed extension enabled the addition of Alate Partners as

Read More
health

VeChain, Renji Hospital and DNV GL Held Strategic Partnership Signing Ceremony To Launch World’s First Blockchain Intelligent Tumor Treatment Center

SHANGHAI, Oct. 27, 2020 /PRNewswire/ — In partnership with VeChain and DNV GL, Renji Hospital, a top-ranked hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has announced the launch of the world’s first blockchain-enabled Intelligent Tumor Treatment Center on October 20, 2020. The Intelligent Tumor Treatment Center is a transparent, efficient, and traceable medical management solution powered by VeChain ToolChainTM.

Sunny Lu, Co-founder and CEO of VeChain & Jidong Zhang, Vice President of Renji Hospital & George Kang, Senior Vice President of DNV GL Group
Sunny Lu, Co-founder and CEO of VeChain & Jidong Zhang, Vice President of Renji Hospital & George Kang, Senior Vice President of DNV GL Group

As strategic partners of this new initiative, VeChain and DNV GL will jointly support the hospital in the quest to improve global public health through state-of-the-art blockchain technology and professional advisory.

VeChain ToolChainTM Powers The World’s First Intelligent Tumor Treatment Center 

The Intelligent Tumor Treatment Center combines the advantages of VeChain blockchain technology with DNV GL’s professional services. It enables full patient ownership of personal medical records, allowing patients to take control of the authorization and medical records data management. Research institutions inside and outside the hospital can use authorized data to improve the efficiency of clinical research, and regulatory agencies can use authorized data to conduct business compliance checks on medical institutions and establish a credit evaluation system.

Zhang Jidong, Vice President of Renji Hospital, said, “The launch of the Intelligent Tumor Treatment Centre intends to enhance high-quality integrated development of Renji Hospital. Moving forward, Renji intends to boost our healthcare facilities with more blockchain-powered use cases and projects, which will be gradually disclosed together with our partners when the time is right.”

George Kang, Senior Vice President of DNV GL Group, said, “Through independent and objective medical evaluation methods, DNV GL intends to provide more services for Renji Hospital to improve its service quality and medical experience, moving to a new stage of higher standards, higher requirements and higher quality.”

Sunny Lu, co-founder and CEO of VeChain, said, “As digital transformation accelerates in the healthcare sector, VeChain will continue to demonstrate its advantages and flexibility as a superior blockchain platform that is suitable for all types of use cases and industries. We are very proud and excited to be contributing to the public health industry by providing the technology for Renji Hospital’s Intelligent Tumor Treatment Centre.”

VeChain Facilitating Digital Transformation To Improve Public Health

In line with the Chinese Government’s 14th Five-Year (2021-2025) Plan for Economic and Social Development, the National Health Commission formulated an official guideline and re-emphasized blockchain technology as an essential innovation and integration of the medical and health industry. VeChain is committed to solving the pain points of digital medical reform through blockchain technology and balancing personal privacy and public interests.

By using the self-developed one-stop data BaaS platform VeChain ToolChainTM , we have many proven cases in the medical sector, including a blockchain powered Clinical Trial Traceability Platform for Bayer China, and a blockchain-enabled medical data management platform named The E-NewHealthLife

Read More
health

Guide Dogs for the Blind and American Foundation for the Blind Launch Extensive Research Study

Two-Year Project To Examine Long-Term Outlook For Guide Dog Use

Guide Dogs for the Blind (GDB) has announced a new partnership with the American Foundation for the Blind (AFB) to embark on an in-depth, two-year research study to examine the long-term outlook for guide dog use in the United States and Canada.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021005166/en/

Courtesy of Guide Dogs for the Blind

This first-of-its-kind study seeks to determine why guide dog ownership is much more prevalent among people who are blind or visually impaired in the United Kingdom, compared to the United States and Canada. To do this, GDB will gather data from those with direct experience with GDB and guide dog schools in Europe.

The study will also include extensive interviews with orientation and mobility (O&M) instructors across North America to assess their training, skills, and knowledge in evaluating whether a guide dog is a viable option for students and clients who are blind or visually impaired. O&M instructors are an important link between people who are blind or visually impaired and the guide dog lifestyle, as they often advise their students about whether a guide dog is right for them as well as help teach O&M skills required to qualify for a guide dog.

“This is the most comprehensive research we’ve ever been a part of, and we hope its findings will help us remove barriers over the next decade for more new clients to experience the life-changing empowerment that a guide dog can bring to their lives,” said Theresa Stern, vice president of outreach, admissions, and alumni services for Guide Dogs for the Blind. “We’re thrilled to partner with the American Foundation for the Blind, a leader in designing research that leads to impactful policies and practices for people who are blind or visually impaired.”

“This collaboration with Guide Dogs for the Blind underscores AFB’s commitment to evidence-based advocacy intended to empower people who are blind or have low vision,” said Dr. L. Penny Rosenblum, AFB director of research. “We are grateful to partner with such a prestigious and historic organization and look forward to gathering and analyzing data that will ultimately better serve those who are visually impaired and anyone who is vested in providing people with vision loss options for independent travel.”

The two-year study will also take into account projections related to the most common occurrences of visual impairment and anticipated changes in demographics over the next 20 years. Its findings will be published in peer-reviewed research journals and will be presented at conferences focused on blindness.

About Guide Dogs for the Blind

Headquartered in San Rafael, Calif., Guide Dogs for the Blind is more than an industry-leading guide dog school; it is a passionate community that serves the visually impaired. GDB prepares highly qualified guide dogs to serve and empower individuals who are blind or visually impaired. All of its services are provided free of charge. GDB receives no government funding. More than

Read More